News & Reviews Not To Be Missed Virtual Journal Educational Resources Bookstore Online Forum Jobs & Resumes Calendar of Events Links Directory

Patient
Resources

Welcome to BoneKEy-Osteovision^®, the Bone Knowledge Environment provided by the International Bone and Mineral Society! If you are visiting us for the first time, please take a moment to register.

BONEKEY APPOINTS PROFESSOR EGO SEEMAN AS CLINICAL EDITOR

We are delighted to announce the appointment of Prof. Ego Seeman, as Clinical Editor. Prof. Seeman will review the clinical literature, annotate important papers for our new Not to be Missed feature (see below) and solicit Commentary and Perspective pieces. His insightful commentary on our field will be a giant step forward for BoneKEy to secure its clinical audience.

BONEKEY LAUNCHES NEW "NOT TO BE MISSED" SECTION

Each month, our editors will review, select, and annotate from the thousands of articles in the Bone field, the most important and ground breaking papers. These papers will form a monthly collection called Not to be Missed.

From our April selections:

Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003 Apr 24;348(17):1656-63. [Abstract]

A new assay for serum FGF23 in phosphate-wasting disorders is reported. The serum level of FGF23 is detectable in most normal subjects. Most patients with oncogenic osteomalacia have elevated levels that are normalized by resection of the tumor. FGF23 levels are also high in some patients with X-linked hypophosphatemia, but a substantial proportion of patients with X-linked hypophosphatemia have normal FGF-23 levels. Is the syndrome heterogeneous or do factors such as treatment with oral phosphate and vitamin D obscure the true role of FGF23? —GJS

Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003 Apr;111(8):1221-30. [Abstract] [Full Text]

A ground-breaking technique was used to isolate RANKL+ stromal cells from human bone marrow by flow cytometry. The cell surface density of RANKL is increased on marrow stromal cells that are isolated from postmenopausal women and also on their B-lymphocytes and T-lymphocytes; the cell surface level of RANKL on all three cell types is reduced to that of premenopausal women by estrogen treatment. RANKL levels on marrow stromal cells, B-cells and T-cells are correlated with markers of bone turnover. Are these changes direct consequences of estrogen deficiency or indirect consequences induced by cytokines? --GJS

Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res. 2003 Mar;18(3):512-20. [Abstract]

This is a wonderful paper. It should be read with the work of Mashiba and others. Incadronate suppressed trabecular remodeling and increased microdamage accumulation. In all these studies the antiresorptive is given to normal animals. Remodeling suppression from a normal tissue mineral density may result in microdamage. Will this occur when remodeling is suppressed in a bone with a low tissue mineral density which increases into the normal range? —ES

See the other lists of Not to be Missed articles from February and March 2003, January 2003, December 2002, November 2002, and October 2002.

Thank you for using BoneKEy-Osteovision - enjoy the BoneKey experience and please provide us with your feedback and suggestions.

QuickSearch

IBMS-JSBMR 2003
June 3-7, 2003
Osaka, Japan

New Online Forum Posting
Dexa scanning follow up